1. Home
  2. AMPL vs NRIX Comparison

AMPL vs NRIX Comparison

Compare AMPL & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amplitude Inc.

AMPL

Amplitude Inc.

HOLD

Current Price

$11.62

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$19.12

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPL
NRIX
Founded
2012
2009
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
AMPL
NRIX
Price
$11.62
$19.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
13
Target Price
$14.91
$27.46
AVG Volume (30 Days)
1.1M
1.8M
Earning Date
02-18-2026
01-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$329,919,000.00
$83,687,000.00
Revenue This Year
$16.61
$59.40
Revenue Next Year
$13.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.78
48.32
52 Week Low
$7.55
$8.18
52 Week High
$14.88
$22.50

Technical Indicators

Market Signals
Indicator
AMPL
NRIX
Relative Strength Index (RSI) 56.61 60.28
Support Level $11.35 $18.78
Resistance Level $12.05 $19.54
Average True Range (ATR) 0.42 0.84
MACD 0.00 -0.21
Stochastic Oscillator 68.61 68.92

Price Performance

Historical Comparison
AMPL
NRIX

About AMPL Amplitude Inc.

Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: